Skip to main content

Advertisement

Table 2 Core details of the references mentioned in the analysis of BMD and RF in Table 1

From: Review article: effects of type 2 diabetes therapies on bone metabolism

References Study category Time of therapy before analysis (months) mean or range HbA1c of the population at the baseline (%) Mean or range Age (years) mean or range Gender (M/F)
[21] RCT 48 7.4 56 M/F
[22] RCT 12 7.4 57 M/F
[26] LC 48 8.4 73 M/F
[39] LC NA NA 62 M/F
[40] RCT 12 7.3 63 F
[58] MA 3–48 6.7–9.9 50–75 M/F
[67] RCT 12 6.0 57 M/F
[68] MA 6–24 6.7–9.9 50–72 M/F
[69] LC 12 8.3 59 M/F
[72] RCT 29 8.2 62 M/F
[73] RCT 43 8.2 63 M/F
[77] RCT 24 6.5–8.5 61 M/F
[78] RCT 11 7.2 61 M/F
[79] RCT 24 7.7 64 M/F
[83] MA 6–37 NA NA M/F
[89] LC 114 NA 61 F
[90] RCT 18 8.6 51 M/F
[91] CC 49 8.0 70 M/F
  1. LC longitudinal cohort, CC case–control study, RCT randomized controlled study, MA meta-analysis of RCT, NA data not available, HbA1c glycated haemoglobin, M, male, F female